IPO - INSMED Inc

Form Type: 8-K

Filing Date: 2025-06-13

Corporate Action: Ipo

Type: New

Accession Number: 000114036125022375

Filing Summary: On June 11, 2025, Insmed Incorporated entered into an Underwriting Agreement with Goldman Sachs & Co. LLC and Leerink Partners LLC. The Company agreed to sell 7,812,500 shares of its common stock to the Underwriters for $91.68 per share, leading to net proceeds of approximately $716.3 million. A 30-day option to purchase up to an additional 1,171,875 shares was also granted. The Offering is conducted under the Company’s shelf registration statement effective since May 19, 2023, with associated prospectus supplements filed on June 11 and June 12, 2025. The sale and purchase of the Firm Shares is expected to occur on June 13, 2025, contingent on customary closing conditions. Customary representations, warranties, and indemnification of the Underwriters are included in the Agreement. The Company announced the Offering commencement and pricing via press releases on June 11, 2025, attached as Exhibits 99.1 and 99.2, respectively.

Form Type: 424B5

Filing Date: 2025-06-12

Corporate Action: Ipo

Type: New

Accession Number: 000114036125022332

Filing Summary: Insmed Inc is offering 7,812,500 shares of its common stock at a public offering price of $96.00 per share, raising an estimated $750 million. The offering is expected to close on June 13, 2025, with Goldman Sachs and Co. LLC, Leerink Partners, BofA Securities, Jefferies, and J.P. Morgan as joint book-running managers. The company is using the proceeds to fund the development of its product candidates, including brensocatib and further commercialization of ARIKAYCE. The document highlights significant risks associated with investing, including dependence on the success of ARIKAYCE and other product candidates, inability to secure regulatory approvals, and competitive market pressures. The recent Phase 2b trial results for the product TPIP have shown positive outcomes, prompting plans for further clinical trials.